content: <html>
  
  <head>
  
  
  
  
  
  </head>
  
  <body lang="EN-US">
  
  <div style="font-family:Times New Roman;">
  
  <div style="border:none;border-top:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED
  STATES</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES
  AND EXCHANGE COMMISSION</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington,
  D.C. 20549</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT
  REPORT</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant
  to Section&nbsp;13 OR 15(d)&nbsp;of</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">The
  Securities Exchange Act of 1934</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date
  of Report (Date of earliest event reported): <b>May&nbsp;23,
  2008 (May&nbsp;22, 2008)</b></font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">ALLOS
  THERAPEUTICS, INC.</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of
  registrant as specified in its charter)</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="1" cellspacing="0" cellpadding="0" width="100%" style="border:none;border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="32%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="32%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">000-29815</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="32%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">54-1655029</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="32%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other
    jurisdiction</font></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission</font></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer</font></p>
    </td>
   </tr>
   <tr>
    <td width="32%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">of
    incorporation)</font></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">File Number)</font></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Identification
    No.)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="1" cellspacing="0" cellpadding="0" width="100%" style="border:none;border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">11080
    CirclePoint Road, Suite&nbsp;200</font></b><font size="2" style="font-size:10.0pt;"><br>
    <b>Westminster, Colorado</b></font></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="49%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">80020</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of
    principal executive offices)</font></p>
    </td>
    <td width="2%" valign="bottom" style="border:none;padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="49%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s
  telephone number, including area code:&nbsp;<b>(303)
  426-6262</b></font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Not applicable</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former
  name or former address, if changed since last report.)</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K
  filing is intended to simultaneously satisfy the filing obligation of the
  registrant under any of the following provisions (see General Instruction A.2.
  below):</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;"> Written communications pursuant to Rule&nbsp;425
  under the Securities Act (17 CFR 230.425)</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;"> Soliciting material pursuant to Rule&nbsp;14a-12
  under the Exchange Act (17 CFR 240.14a-12)</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;"> Pre-commencement communications pursuant
  to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="2" style="font-size:10.0pt;"> Pre-commencement communications pursuant
  to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
  
  <div style="border:none;border-bottom:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='',FILE='C:\JMS\bvanga\08-14573-3\task2956544\14573-3-ba.htm',USER='bvanga',CD='May 22 23:34 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;1
  &#151; Registrant&#146;s Business and Operations</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
  1.01.&nbsp; Entry into a Material Definitive Agreement.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On May&nbsp;22,
  2008, Allos Therapeutics,&nbsp;Inc. (the &#147;Company&#148;) entered into a Purchase
  Agreement (the &#147;Purchase Agreement&#148;) with Merrill Lynch&nbsp;&amp; Co., Merrill
  Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated (&#147;Merrill Lynch&#148;), as
  representative of the several underwriters named therein (collectively, the &#147;Underwriters&#148;).&nbsp;
  Subject to the terms and conditions of the Purchase Agreement, the Company
  agreed to sell to the Underwriters, and the Underwriters agreed to purchase
  from the Company, an aggregate of up to 10,800,000 shares of the Company&#146;s
  authorized but previously unissued common stock, par value $0.001 (&#147;Common
  Stock&#148;) at a public offering price of $5.64 per share.&nbsp; The resulting
  aggregate net proceeds to the Company from this Common Stock offering after an
  underwriting discount totaling approximately $3.7&nbsp;million, but before
  expenses, will be approximately $57.3 million. The Company also granted the
  Underwriters a 30-day option to purchase up to 1,620,000 additional shares of
  Common Stock to cover overallotments, if any (such shares, together with the
  other shares to be purchased under the Purchase Agreement, the &#147;Shares&#148;). The
  Underwriters&#146; obligations to purchase the Shares is subject to the satisfaction
  of certain customary closing conditions, including receipt of legal opinions
  and approval of legal matters by their respective counsels.&nbsp; The Company
  has agreed to indemnify the Underwriters against certain liabilities, including
  liabilities under the Securities Act of 1933, as amended (the &#147;Act&#148;), or to
  contribute to the payments the Underwriters may be required to make in respect
  of these liabilities.&nbsp; Subject to certain exceptions, the Company and all
  of the Company&#146;s directors and certain of its executive officers also agreed
  not to sell or transfer any Common Stock held by them for 90 days after May&nbsp;22,
  2008 without first obtaining the written consent of Merrill Lynch.&nbsp; A copy
  of the Purchase Agreement is attached hereto as Exhibit&nbsp;1.1 and is
  incorporated herein by reference.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The closing of the
  sale of 10,800,000 of the Shares is scheduled to occur on or about May&nbsp;29,
  2008.&nbsp; The Shares have been registered pursuant to a registration
  statement on Form&nbsp;S-3 (Registration Statement No.&nbsp;333-143198) filed
  with the Securities and Exchange Commission under the Act on May&nbsp;23, 2007.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Warburg Pincus
  Private Equity VIII, L.P. has indicated an interest in purchasing up to
  3,500,000 Shares at the public offering price.&#160;
  Baker Brothers Life Sciences, L.P., and certain other affiliated funds,
  have also indicated an interest in purchasing up to 1,500,000 Shares at the public
  offering price.&#160; Because indications of
  interest are not binding agreements or commitments to purchase, these entities
  may purchase fewer or no shares in this offering.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing is a
  summary of the terms of the Purchase Agreement. Such summary does not purport
  to be complete and is qualified in its entirety by reference to the full text
  of the Purchase Agreement, a copy of which is attached hereto and incorporated
  herein by reference.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;7
  &#151; Regulation FD</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
  7.01 Regulation FD Disclosure.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The press release
  announcing the pricing of the public offering is attached hereto as Exhibit&nbsp;99.1
  and incorporated herein by reference.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In accordance with
  General Instruction B.2. of Form&nbsp;8-K, the information presented under this
  Item&nbsp;7.01 and attached as Exhibit&nbsp;99.1 shall not be deemed &#147;filed&#148;
  for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as
  amended, nor shall it be deemed incorporated by reference in any filing under
  the Securities Act of 1933, as amended, except as expressly set forth by
  specific reference in such a filing.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Forward-Looking
  Statements</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This Current
  Report on Form&nbsp;8-K contains forward-looking statements, including
  statements related to the sale by the Company of its securities. Words such as &#147;believes&#148;,
  &#147;anticipates&#148;, &#147;plans&#148;, &#147;expects&#148;, &#147;intend&#148;, &#147;will&#148;, &#147;goal&#148;, &#147;potential&#148; and
  similar expressions are intended to identify forward-looking statements. These
  forward-looking statements are based upon the Company&#146;s current expectations
  and involve risks and uncertainties. Actual </font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\bvanga\08-14573-3\task2956544\14573-3-ba.htm',USER='bvanga',CD='May 22 23:34 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">results and the timing of
  events could differ materially from those anticipated in such forward-looking
  statements as a result of these risks and uncertainties, which include, without
  limitation, risks related to the Company&#146;s ability to meet the closing
  conditions required for the consummation of the offering, risks related to the
  fact Warburg Pincus Private Equity VIII, L.P. and Baker Brothers Life Sciences,
  L.P. and certain of its affiliated funds may purchase fewer than all of the
  Shares they have indicated an interest in purchasing or they may purchase no
  shares in this offering, and other risks detailed in the Registration Statement
  covering the offering and in the Company&#146;s filings with the Securities and
  Exchange Commission, including its Annual Report on Form&nbsp;10-K for the year
  ended December&nbsp;31, 2007 and periodic reports on Form&nbsp;10-Q and Form&nbsp;8-K.
  Do not place undue reliance on these forward-looking statements, which speak
  only as of the date of this report. All forward-looking statements are
  qualified in their entirety by this cautionary statement, and, except where
  required by law, the Company undertakes no obligation to revise or update any
  forward-looking statements to reflect events or circumstances after the date of
  this report.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Section&nbsp;9&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements and Exhibits</font></b></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements and Exhibits.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="93%" style="border-collapse:collapse;margin-left:36.7pt;width:93.2%;">
   <tr>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.14%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font></p>
    </td>
    <td width="1%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:1.18%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="91%" valign="top" style="padding:0in .7pt 0in .7pt;width:91.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase Agreement,
    dated May&nbsp;22, 2008, by and among Allos Therapeutics,&nbsp;Inc. and
    Merrill Lynch&nbsp;&amp; Co., Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith
    Incorporated as representative of the several underwriters party thereto.</font></p>
    </td>
   </tr>
   <tr>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.14%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="1%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:1.18%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="91%" valign="top" style="padding:0in .7pt 0in .7pt;width:91.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.14%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font></p>
    </td>
    <td width="1%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:1.18%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="91%" valign="top" style="padding:0in .7pt 0in .7pt;width:91.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Opinion of Cooley
    Godward Kronish LLP.</font></p>
    </td>
   </tr>
   <tr>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.14%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="1%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:1.18%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="91%" valign="top" style="padding:0in .7pt 0in .7pt;width:91.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.14%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.1</font></p>
    </td>
    <td width="1%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:1.18%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="91%" valign="top" style="padding:0in .7pt 0in .7pt;width:91.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent of Cooley
    Godward Kronish LLP. Reference is made to Exhibit&nbsp;5.1.</font></p>
    </td>
   </tr>
   <tr>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.14%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="1%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:1.18%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="91%" valign="top" style="padding:0in .7pt 0in .7pt;width:91.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="7%" valign="top" style="padding:0in .7pt 0in .7pt;width:7.14%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
    </td>
    <td width="1%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:1.18%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="91%" valign="top" style="padding:0in .7pt 0in .7pt;width:91.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release, dated
    May&nbsp;23, 2008, entitled &#147;Allos
    Therapeutics Announces Pricing of Public Offering of 10,800,000 Shares of
    Common Stock.&#148;</font></p>
    </td>
   </tr>
  </table>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>
  
  <div style="margin:0in 0in .0001pt;text-indent:0in;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\bvanga\08-14573-3\task2956544\14573-3-ba.htm',USER='bvanga',CD='May 22 23:34 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities
  Exchange Act of 1934, the registrant has duly caused this report to be signed
  on its behalf by the undersigned hereunto duly authorized.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:&#160;&#160;&#160; May&nbsp;23, 2008</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="52%" valign="top" style="padding:0in .7pt 0in .7pt;width:52.22%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="4%" valign="top" style="padding:0in .7pt 0in .7pt;width:4.42%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.36%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ALLOS THERAPEUTICS, INC.</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="52%" valign="top" style="padding:0in .7pt 0in .7pt;width:52.22%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="4%" valign="top" style="padding:0in .7pt 0in .7pt;width:4.42%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.36%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="52%" valign="top" style="padding:0in .7pt 0in .7pt;width:52.22%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="4%" valign="top" style="padding:0in .7pt 0in .7pt;width:4.42%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.36%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="52%" valign="top" style="padding:0in .7pt 0in .7pt;width:52.22%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="4%" valign="top" style="padding:0in .7pt 0in .7pt;width:4.42%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:&nbsp;</font></p>
    </td>
    <td width="43%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:43.36%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Marc H. Graboyes</font></p>
    </td>
   </tr>
   <tr>
    <td width="52%" valign="top" style="padding:0in .7pt 0in .7pt;width:52.22%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="4%" valign="top" style="padding:0in .7pt 0in .7pt;width:4.42%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="43%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:43.36%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Marc H. Graboyes</font></p>
    </td>
   </tr>
   <tr>
    <td width="52%" valign="top" style="padding:0in .7pt 0in .7pt;width:52.22%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="4%" valign="top" style="padding:0in .7pt 0in .7pt;width:4.42%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Its:&nbsp;</font></p>
    </td>
    <td width="43%" valign="top" style="padding:0in .7pt 0in .7pt;width:43.36%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Senior Vice President,
    General Counsel and Secretary</font></p>
    </td>
   </tr>
  </table>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>
  
  <div style="margin:0in 0in .0001pt;text-indent:0in;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\bvanga\08-14573-3\task2956544\14573-3-ba.htm',USER='bvanga',CD='May 22 23:34 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-indent:0in;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT INDEX</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="94%" style="border-collapse:collapse;margin-left:.4in;width:94.0%;">
   <tr>
    <td width="8%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:8.62%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.68%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="88%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:88.7%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="8%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:8.62%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">1.1</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="88%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:88.7%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Purchase Agreement,
    dated May&nbsp;22, 2008, by and among Allos Therapeutics,&nbsp;Inc. and
    Merrill Lynch&nbsp;&amp; Co., Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith
    Incorporated as representative of the several underwriters party thereto.</font></p>
    </td>
   </tr>
   <tr>
    <td width="8%" valign="top" style="padding:0in .7pt 0in .7pt;width:8.62%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.7%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="8%" valign="top" style="padding:0in .7pt 0in .7pt;width:8.62%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5.1</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.7%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Opinion of Cooley
    Godward Kronish LLP.</font></p>
    </td>
   </tr>
   <tr>
    <td width="8%" valign="top" style="padding:0in .7pt 0in .7pt;width:8.62%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.7%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="8%" valign="top" style="padding:0in .7pt 0in .7pt;width:8.62%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">23.1</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.7%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consent of Cooley
    Godward Kronish LLP. Reference is made to Exhibit&nbsp;5.1.</font></p>
    </td>
   </tr>
   <tr>
    <td width="8%" valign="top" style="padding:0in .7pt 0in .7pt;width:8.62%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.7%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="8%" valign="top" style="padding:0in .7pt 0in .7pt;width:8.62%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.68%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.7%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release, dated
    May&nbsp;23, 2008, entitled &#147;Allos
    Therapeutics Announces Pricing of Public Offering of 10,800,000 Shares of
    Common Stock.&#148;</font></p>
    </td>
   </tr>
  </table>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\bvanga\08-14573-3\task2956544\14573-3-ba.htm',USER='bvanga',CD='May 22 23:34 2008' -->
  
  
  </body>
  
  </html>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "a08-14573_38k.htm", "description": "8-K", "secsgml_size_bytes": 43438}]
metadata_filer: {"company-data": {"conformed-name": "ALLOS THERAPEUTICS INC", "cik": "0001097264", "assigned-sic": "2834", "irs-number": "541655029", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-29815", "film-number": "08856299"}, "business-address": {"street1": "11080 CIRCLEPOINT ROAD", "street2": "SUITE 200", "city": "WESTMINSTER", "state": "CO", "zip": "80020", "phone": "3034266262"}, "mail-address": {"street1": "11080 CIRCLEPOINT ROAD", "street2": "SUITE 200", "city": "WESTMINSTER", "state": "CO", "zip": "80020"}}
text: UNITED
  STATES
  SECURITIES
  AND EXCHANGE COMMISSION
  Washington,
  D.C. 20549
  FORM 8-K
  CURRENT
  REPORT
  Pursuant
  to Section 13 OR 15(d) of
  The
  Securities Exchange Act of 1934
  Date
  of Report (Date of earliest event reported):
  May 23,
  2008 (May 22, 2008)
  ALLOS
  THERAPEUTICS, INC.
  (Exact name of
  registrant as specified in its charter)
  Delaware
  000-29815
  54-1655029
  (State or other
    jurisdiction
  (Commission
  (IRS Employer
  of
    incorporation)
  File Number)
  Identification
    No.)
  11080
    CirclePoint Road, Suite 200
  Westminster, Colorado
  80020
  (Address of
    principal executive offices)
  (Zip Code)
  Registrant's
  telephone number, including area code:
  (303)
  426-6262
  Not applicable
  (Former
  name or former address, if changed since last report.)
  Check the appropriate box below if the Form 8-K
  filing is intended to simultaneously satisfy the filing obligation of the
  registrant under any of the following provisions (see General Instruction A.2.
  below):
  o
  Written communications pursuant to Rule 425
  under the Securities Act (17 CFR 230.425)
  o
  Soliciting material pursuant to Rule 14a-12
  under the Exchange Act (17 CFR 240.14a-12)
  o
  Pre-commencement communications pursuant
  to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  o
  Pre-commencement communications pursuant
  to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
  Section 1
  — Registrant's Business and Operations
  Item
  1.01.  Entry into a Material Definitive Agreement.
  On May 22,
  2008, Allos Therapeutics, Inc. (the "Company") entered into a Purchase
  Agreement (the "Purchase Agreement") with Merrill Lynch & Co., Merrill
  Lynch, Pierce, Fenner & Smith Incorporated ("Merrill Lynch"), as
  representative of the several underwriters named therein (collectively, the "Underwriters"). 
  Subject to the terms and conditions of the Purchase Agreement, the Company
  agreed to sell to the Underwriters, and the Underwriters agreed to purchase
  from the Company, an aggregate of up to 10,800,000 shares of the Company's
  authorized but previously unissued common stock, par value $0.001 ("Common
  Stock") at a public offering price of $5.64 per share.  The resulting
  aggregate net proceeds to the Company from this Common Stock offering after an
  underwriting discount totaling approximately $3.7 million, but before
  expenses, will be approximately $57.3 million. The Company also granted the
  Underwriters a 30-day option to purchase up to 1,620,000 additional shares of
  Common Stock to cover overallotments, if any (such shares, together with the
  other shares to be purchased under the Purchase Agreement, the "Shares"). The
  Underwriters' obligations to purchase the Shares is subject to the satisfaction
  of certain customary closing conditions, including receipt of legal opinions
  and approval of legal matters by their respective counsels.  The Company
  has agreed to indemnify the Underwriters against certain liabilities, including
  liabilities under the Securities Act of 1933, as amended (the "Act"), or to
  contribute to the payments the Underwriters may be required to make in respect
  of these liabilities.  Subject to certain exceptions, the Company and all
  of the Company's directors and certain of its executive officers also agreed
  not to sell or transfer any Common Stock held by them for 90 days after May 22,
  2008 without first obtaining the written consent of Merrill Lynch.  A copy
  of the Purchase Agreement is attached hereto as Exhibit 1.1 and is
  incorporated herein by reference.
  The closing of the
  sale of 10,800,000 of the Shares is scheduled to occur on or about May 29,
  2008.  The Shares have been registered pursuant to a registration
  statement on Form S-3 (Registration Statement No. 333-143198) filed
  with the Securities and Exchange Commission under the Act on May 23, 2007.
  Warburg Pincus
  Private Equity VIII, L.P. has indicated an interest in purchasing up to
  3,500,000 Shares at the public offering price. 
  Baker Brothers Life Sciences, L.P., and certain other affiliated funds,
  have also indicated an interest in purchasing up to 1,500,000 Shares at the public
  offering price.  Because indications of
  interest are not binding agreements or commitments to purchase, these entities
  may purchase fewer or no shares in this offering.
  The foregoing is a
  summary of the terms of the Purchase Agreement. Such summary does not purport
  to be complete and is qualified in its entirety by reference to the full text
  of the Purchase Agreement, a copy of which is attached hereto and incorporated
  herein by reference.
  Section 7
  — Regulation FD
  Item
  7.01 Regulation FD Disclosure.
  The press release
  announcing the pricing of the public offering is attached hereto as Exhibit 99.1
  and incorporated herein by reference.
  In accordance with
  General Instruction B.2. of Form 8-K, the information presented under this
  Item 7.01 and attached as Exhibit 99.1 shall not be deemed "filed"
  for purposes of Section 18 of the Securities Exchange Act of 1934, as
  amended, nor shall it be deemed incorporated by reference in any filing under
  the Securities Act of 1933, as amended, except as expressly set forth by
  specific reference in such a filing.
  Forward-Looking
  Statements
  This Current
  Report on Form 8-K contains forward-looking statements, including
  statements related to the sale by the Company of its securities. Words such as "believes",
  "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and
  similar expressions are intended to identify forward-looking statements. These
  forward-looking statements are based upon the Company's current expectations
  and involve risks and uncertainties. Actual
  2
  results and the timing of
  events could differ materially from those anticipated in such forward-looking
  statements as a result of these risks and uncertainties, which include, without
  limitation, risks related to the Company's ability to meet the closing
  conditions required for the consummation of the offering, risks related to the
  fact Warburg Pincus Private Equity VIII, L.P. and Baker Brothers Life Sciences,
  L.P. and certain of its affiliated funds may purchase fewer than all of the
  Shares they have indicated an interest in purchasing or they may purchase no
  shares in this offering, and other risks detailed in the Registration Statement
  covering the offering and in the Company's filings with the Securities and
  Exchange Commission, including its Annual Report on Form 10-K for the year
  ended December 31, 2007 and periodic reports on Form 10-Q and Form 8-K.
  Do not place undue reliance on these forward-looking statements, which speak
  only as of the date of this report. All forward-looking statements are
  qualified in their entirety by this cautionary statement, and, except where
  required by law, the Company undertakes no obligation to revise or update any
  forward-looking statements to reflect events or circumstances after the date of
  this report.
  Section 9               Financial Statements and Exhibits
  Item 9.01               Financial Statements and Exhibits.
  (d)           Exhibits.
  1.1
  Purchase Agreement,
    dated May 22, 2008, by and among Allos Therapeutics, Inc. and
    Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith
    Incorporated as representative of the several underwriters party thereto.
  5.1
  Opinion of Cooley
    Godward Kronish LLP.
  23.1
  Consent of Cooley
    Godward Kronish LLP. Reference is made to Exhibit 5.1.
  99.1
  Press Release, dated
    May 23, 2008, entitled "Allos
    Therapeutics Announces Pricing of Public Offering of 10,800,000 Shares of
    Common Stock."
  3
  SIGNATURES
  Pursuant to the requirements of the Securities
  Exchange Act of 1934, the registrant has duly caused this report to be signed
  on its behalf by the undersigned hereunto duly authorized.
  Dated:    May 23, 2008
  ALLOS THERAPEUTICS, INC.
  By:
  /s/ Marc H. Graboyes
  Marc H. Graboyes
  Its:
  Senior Vice President,
    General Counsel and Secretary
  4
  EXHIBIT INDEX
  Exhibit No.
  Description
  1.1
  Purchase Agreement,
    dated May 22, 2008, by and among Allos Therapeutics, Inc. and
    Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith
    Incorporated as representative of the several underwriters party thereto.
  5.1
  Opinion of Cooley
    Godward Kronish LLP.
  23.1
  Consent of Cooley
    Godward Kronish LLP. Reference is made to Exhibit 5.1.
  99.1
  Press Release, dated
    May 23, 2008, entitled "Allos
    Therapeutics Announces Pricing of Public Offering of 10,800,000 Shares of
    Common Stock."
  5